bluebird bio, Inc. BLUE · Stock Open bluebird bio, Inc. in new tab
bluebird bio, Inc. Analysis (BLUE)
Is bluebird bio, Inc. a good investment? bluebird bio, Inc. (BLUE) is currently trading at 4.97 USD.
Earnings Schedule: bluebird bio, Inc. is expected to release its next earnings report on May 12, 2026. The market consensus estimate for Forward EPS is -0.65.
Investor FAQ
Does bluebird bio, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is bluebird bio, Inc.?
bluebird bio, Inc. is classified as a Stock. You can compare it against 5 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be May 12, 2026. The company currently has a trailing EPS of -20.59.
Company Profile
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disease (SCD) and a history of vaso-occlusive events; and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts. As of May 29, 2025, bluebird bio, Inc. was taken private.
| Split Date | Split Ratio to 1 |
|---|---|
| Nov. 5, 2021 | 1.54 |
| Dec. 13, 2024 | 1:20 |
Community Discussion